Jan 8 (Reuters) - Xenon Pharmaceuticals Inc:
* XENON PHARMACEUTICALS OUTLINES KEY MILESTONES FOR 2018 * XENON PHARMACEUTICALS INC - EXPECT TO HAVE ONGOING XEN1101 PHASE 1 CLINICAL TRIAL COMPLETED BY MID-YEAR
* XENON PHARMACEUTICALS INC - IN SECOND HALF OF THIS YEAR, ANTICIPATE HAVING COMPLETED XEN901 PHASE 1 CLINICAL TRIAL
* XENON PHARMACEUTICALS INC - ANTICIPATE THAT BOTH XEN1101 AND XEN901 COULD BE IN PHASE 2 DEVELOPMENT BY END OF THIS YEAR
* XENON PHARMACEUTICALS INC - AS OF DECEMBER 31, 2017, CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $43.7 MILLION
* XENON PHARMACEUTICALS INC - BASED ON CURRENT ASSUMPTIONS, XENON ANTICIPATES HAVING SUFFICIENT CASH TO FUND OPERATIONS INTO MID-2019 Source text for Eikon: Further company coverage:
 